Frontlight ResearchEarly access
Chronic myeloid leukaemia trials in Germany
16 of 19 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleStudy to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
- Where
- Erlangen, Frankfurt am Main, Hamburg
- Age
- 1 year to 18 years
- People
- 50 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07354074 - Phase 2Not yet taking people in GermanyEfficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations
- Where
- Aachen, Berlin, Chemnitz, Hanover, Jena, Leipzig, Mannheim, Ulm
- Age
- 18 years and over
- People
- 50
- Run by
- Thomas Ernst, Prof. Dr. med.
See details and how to joinNCT07789574 · EU 2025-523491-23-00 - Phase 4Taking peopleAsciminib Roll-over Study
- Where
- Aachen, Augsburg, Bad Saarow, Berlin, Bonn, Chemnitz, Dresden, Erlangen, Frankfurt Am Main, Freiburg im Breisgau, Halle (Saale), Hamburg, Jena, Kiel, Leipzig, Mannheim, Marburg, Muenchen, Munich, Regensburg, Ulm, Wuerzburg
- Age
- 7 years to 100 years
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - Phase 1Not yet taking people in GermanyA Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
- Where
- Berlin, Munich, Ulm
- People
- 225 worldwide
- Run by
- Janssen Cilag International
See details and how to join2026-525234-39-00 - Phase 1/2Taking peopleA Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
- Where
- Aachen, Berlin, Frankfurt Am Main, Hanover, Jena, Mannheim, Munich
- Age
- 18 years to 64 years
- People
- 330 worldwide
- Run by
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
See details and how to joinNCT06163430 · EU 2023-507677-18-00 - Phase 2/3Taking peopleA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Where
- Brunswick, Freiburg im Breisgau, Halle Saale, Heidelberg
- Age
- 18 years and over
- People
- 316 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00 - Phase 4Taking peopleRegistry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
- Where
- Augsburg, Berlin, Bochum, Brunswick, Chemnitz, Cologne, Dresden, Erfurt, Essen, Frankfurt Am Main, Greifswald, Halle (Saale), Hamburg, Hanover, Herne, Jena, Kiel, Leipzig, Magdeburg, Muenster, Munich, Regensburg, Rostock, Tuebingen, Ulm
- Age
- 18 years and over
- People
- 365 worldwide
- Run by
- Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 - Phase 1/2Taking peopleVenetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
- Where
- Aachen, Cologne, Duesseldorf, Frankfurt Am Main, Jena, Munich
- Age
- 18 years and over
- People
- 38
- Run by
- Heinrich-Heine University, Duesseldorf
See details and how to joinNCT05807932 · EU 2024-514688-24-00 - Phase 2Active, not recruiting(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Where
- Aachen, Freiburg im Breisgau, Lübeck, Mannheim
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00 - Phase 3Taking peopleStudy of Olverembatinib (HQP1351) in Patients With CML-CP
- Where
- Berlin, Dresden, Leipzig
- Age
- 18 years and over
- People
- 333 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06423911 · EU 2024-511495-32-00 - Phase 2Not yet taking people in GermanyAsciminib Frontline Risk Adapted
- Where
- Jena
- Age
- 18 years and over
- People
- 200
- Run by
- Prof. Dr. med. Andreas Hochhaus
See details and how to joinNCT07804901 · EU 2026-528103-13-00 - Phase 2Not yet taking people in GermanyStudy to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia.
- Where
- Dresden, Erlangen, Essen, Frankfurt Am Main, Hamburg
- Age
- Up to 17 years
- People
- 16 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-522138-29-00 - Phase 2CompletedA Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
- Where
- Brunswick, Luebeck
- Age
- 18 years and over
- People
- 332 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01 - Phase 1/2Not yet taking people in GermanyA Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
- Where
- Berlin, Dresden, Heidelberg, Jena, Leipzig, Munich, Ulm
- Age
- 18 years and over
- People
- 64 worldwide
- Run by
- Servier
See details and how to joinNCT07719348 · EU 2025-525128-88-00 - Phase 1Taking peopleA Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
- Where
- Aachen, Berlin, Frankfurt Am Main, Homburg, Jena, Mannheim, Rostock
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- Enliven Therapeutics
See details and how to joinNCT05304377 · EU 2023-503335-18-00 - Phase 1/2CompletedClinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Where
- Berlin, Brunswick, Leipzig
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Aptose Biosciences Inc.
See details and how to joinNCT03850574 · EU 2023-503244-14-00